Articles |

Clinical Insights Into the Pathogenesis of Primary Pulmonary Hypertension FREE TO VIEW

Stuart Rich
Author and Funding Information

From the Section of Cardiology, Rush-Presbyterian-St. Luke's Medical Center, Chicago

Stuart Rich, MD, The Rush Heart Institute, Center for Pulmonary Heart Disease, Rush-Presbyterian-St. Luke's Medical Center, 1725 W Harrison St, Suite 020, Chicago, IL; email: srich@rpslmc.edu

1998 by the American College of Chest Physicians

Chest. 1998;114(3_Supplement):237S-241S. doi:10.1378/chest.114.3_Supplement.237S
Text Size: A A A
Published online


Because of the lack of adequate animal models, much of our knowledge of the pathogenesis of primary pulmonary hypertension has come from clinical experiences. The clinical response to vasodilators, prostenoids, and anticoagulants as treatments appear to correlate with the pathologic changes of medial hypertrophy, intimal proliferation, and thrombosis. Endothelial dysfunction, as a primary abnormality in primary pulmonary hypertension, provides an explanation for the pathologic and clinical expression of the disease in its various forms. Other clinical features of the disease, such as age of onset and rapidity of progression, may be influenced by triggers of the disease process and underlying individual genetic susceptibility. As we have been able to correlate the spectrum of clinical observations with advances in vascular biology, newer, more focused and effective therapies should begin to emerge.




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543